Clinical efficacy and cost–effectiveness of rosuvastatin
PC Deedwania, DG Smith - Expert Review of Pharmacoeconomics …, 2007 - Taylor & Francis
Rosuvastatin, which was approved by the FDA in 2003 and has been available in Europe
since 2002, is the newest and most efficacious of the currently available 3-hydroxy-3 …
since 2002, is the newest and most efficacious of the currently available 3-hydroxy-3 …
[PDF][PDF] ROSUVASTATIN: BEYOND THE
FCMGA Maria - Trials, 2006 - academia.edu
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis
of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A …
of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A …
[PDF][PDF] 安全性の問題で市場撤退となったセリバスタチンの最新情報と米国の市販後安全性監視システムの解析
齋藤充生， 平田睦子， 三宅真二， 長谷川隆一 - 国立医薬品食品衛生研究所 …, 2005 - nihs.go.jp
Among the opened, unpublished data, was the finding that cerivastatin obviously induced
myopathy in a dose-dependent manner when administrated as monotherapy. As for other …
myopathy in a dose-dependent manner when administrated as monotherapy. As for other …
[引用][C] Effect of different doses of rosuvastatin on carotid atherosclerosis in Chinese patients: a Meta-analysis
Y Xue, L Nan, W Haibing
[引用][C] 2016 ESC/EAS Preporuke za lečenje dislipidemija
MT Cooney - European Heart Journal, 2016
[引用][C] Effect of rosuvastatin on acute coronary syndrome complicated with mild to moderate renal insufficiency
X Hua, H Zhangjiang, LIN Poqing, LEI Gang… - J Clin …, 2012 - lcxxgen.whuhzzs.com
Effect of rosuvastatin on acute coronary syndrome complicated with mild to moderate renal
insufficiency Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …
insufficiency Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …